CTOs on the Move

Del Norte Clinics

www.dnci.org

 
Del Norte Clinics is a Yuba City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dnci.org
  • 935 Market St
    Yuba City, CA USA 95991
  • Phone: 530.751.0850

Executives

Name Title Contact Details

Similar Companies

EST Analytical

EST Analytical is a Fairfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medicorp Inc

Medicorp Inc is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osprey Medical

Osprey Medical is a medical device company incorporated in 2005 with operations based in Minnetonka, Minnesota, USA. The Company is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. Osprey Medical`s core technologies originated from research conducted by Dr. David Kaye at Melbourne`s Baker IDI Heart and Diabetes Institute

Merz Aesthetics

Merz Aesthetics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HeartBeam

HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack